Drugs / IPH5201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04261075 | Mar 2020 → Jun 2022 | neoplasm | MedImmune LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05742607 | Jun 2023 → Jun 2027 expected | non-small cell lung carcinoma | Innate Pharma | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPH5201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05742607 ↗ |